228 related articles for article (PubMed ID: 26433850)
1. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
Chung CG; Poligone B
Dermatol Clin; 2015 Oct; 33(4):787-805. PubMed ID: 26433850
[TBL] [Abstract][Full Text] [Related]
2. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.
Fierro MT; Doveil GC; Quaglino P; Savoia P; Verrone A; Bernengo MG
Dermatology; 1997; 194(3):268-72. PubMed ID: 9187846
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
4. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma.
Nguyen CV; Bohjanen KA
Dermatol Clin; 2015 Oct; 33(4):683-96. PubMed ID: 26433841
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies for cutaneous T-cell lymphomas.
Horwitz SM
Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
7. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for mycosis fungoides and the Sézary syndrome.
Rosen ST; Foss FM
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1109-16. PubMed ID: 8522487
[TBL] [Abstract][Full Text] [Related]
10. Mycosis fungoides: pathophysiology and emerging therapies.
Duvic M; Foss FM
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S21-8. PubMed ID: 18086343
[TBL] [Abstract][Full Text] [Related]
11. Bexarotene and systemic disease progression in CTCL?
Dummer R; Hauschild A; Skalsky J; Burg G; Weichenthal M
J Am Acad Dermatol; 2006 Aug; 55(2):365-6; author reply 366. PubMed ID: 16844539
[No Abstract] [Full Text] [Related]
12. Cutaneous T-cell lymphoma's confounding nature.
Schmidt C
J Natl Cancer Inst; 2012 Jun; 104(11):806-8. PubMed ID: 22673589
[No Abstract] [Full Text] [Related]
13. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
Scarisbrick JJ; Child FJ; Clift A; Sabroe R; Whittaker SJ; Spittle M; Russell-Jones R
Br J Dermatol; 2001 May; 144(5):1010-5. PubMed ID: 11359390
[TBL] [Abstract][Full Text] [Related]
14. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy SA
Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
[TBL] [Abstract][Full Text] [Related]
16. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Zirlik K; Nashan D; Veelken H
Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
[No Abstract] [Full Text] [Related]
17. Targeted therapies for cutaneous T-cell lymphomas.
Kaplan JB; Guitart J; Giles FJ
Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
Devata S; Wilcox RA
Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912
[TBL] [Abstract][Full Text] [Related]
19. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
20. Alitretinoin in the treatment of cutaneous T-cell lymphoma.
Kaemmerer T; Stadler PC; Helene Frommherz L; Guertler A; Einar French L; Reinholz M
Cancer Med; 2021 Oct; 10(20):7071-7078. PubMed ID: 34435474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
